BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26045814)

  • 1. Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
    Liu Y; Wang P; Li S; Yin L; Shen H; Liu R
    Int J Clin Exp Pathol; 2015; 8(3):3027-35. PubMed ID: 26045814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
    Abeni E; Salvi A; Marchina E; Traversa M; Arici B; De Petro G
    Int J Oncol; 2017 Jul; 51(1):128-144. PubMed ID: 28560380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
    Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
    Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
    Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
    Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
    Jiang X; Zhang W; Li L; Xie S
    Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
    Peveling-Oberhag J; Döring C; Hartmann S; Filmann N; Mertens A; Piiper A; Herrmann E; Hansmann ML; Zeuzem S; Trojan J; Welker MW
    Clin Sci (Lond); 2015 Jan; 128(1):29-37. PubMed ID: 24959956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
    Masuda M; Chen WY; Miyanaga A; Nakamura Y; Kawasaki K; Sakuma T; Ono M; Chen CL; Honda K; Yamada T
    Mol Cell Proteomics; 2014 Jun; 13(6):1429-38. PubMed ID: 24643969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
    Nishida N; Kitano M; Sakurai T; Kudo M
    Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNAs and genes contributing to the generation of cancer stem cells in hepatocellular carcinoma identified by RNA sequencing analysis.
    Cao L; Zhang Q; Cheng S; Chen Z; Hua Z; Yang J; Liu D; Cui N
    Oncol Rep; 2016 Nov; 36(5):2619-2624. PubMed ID: 27667473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
    Makarova AS; Lazarevich NL
    Klin Lab Diagn; 2013 Oct; (10):66-8, 34-7. PubMed ID: 24640100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
    Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
    Liu J; Qiu WC; Shen XY; Sun GC
    Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Label-retaining liver cancer cells are relatively resistant to sorafenib.
    Xin HW; Ambe CM; Hari DM; Wiegand GW; Miller TC; Chen JQ; Anderson AJ; Ray S; Mullinax JE; Koizumi T; Langan RC; Burka D; Herrmann MA; Goldsmith PK; Stojadinovic A; Rudloff U; Thorgeirsson SS; Avital I
    Gut; 2013 Dec; 62(12):1777-86. PubMed ID: 23411027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.